Welcome to our dedicated page for FATE THERAPEUTICS SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FATE THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FATE THERAPEUTICS's regulatory disclosures and financial reporting.
Fate Therapeutics shareholder Redmile Group filed an amended Form 4 to update the terms of cash-settled swap positions tied to Fate common stock. The amendment corrects the reference price associated with swap agreements that were internally reorganized.
The swaps, representing an economic interest in 266,280 notional shares of common stock per reported leg, were novated from RedCo II Master Fund to two wholly owned subsidiaries on a pro‑rata basis, for no consideration and with no change in other terms. Footnotes state this internal reorganization caused no change in the aggregate beneficial ownership or economic exposure of Redmile or its principal Jeremy Green.
The swaps are cash‑settled and give Redmile-managed clients economic exposure to Fate’s share price movements without voting, investment, or dispositive control over Fate shares. Cash flows at settlement depend on the difference between the corrected reference price of $5.84 per notional share and the market price at close‑out.
Fate Therapeutics insider RedCo II Master Fund, L.P., an investment vehicle managed by Redmile Group, completed an internal reorganization of its holdings. RedCo II distributed its Fate Therapeutics common stock, Class A convertible preferred stock, pre-funded warrants, and cash-settled swaps pro rata and in kind to two wholly owned subsidiaries, for no consideration.
Following this, RedCo II no longer has voting or dispositive power over these securities, is no longer a more-than-10% beneficial owner, and will be dissolved. The filing states the reorganization caused no change in the aggregate beneficial ownership of Redmile Group or its principal, Jeremy Green.
Fate Therapeutics’ large shareholder Redmile Group has updated its ownership report following an internal reorganization of its investment vehicles. RedCo II Master Fund, L.P. transferred all its Fate securities to two wholly owned SPVs, including RedCo II Offshore SPV LLC, for no consideration.
After the reorganization, RedCo II Master Fund no longer beneficially owns more than 5% of Fate’s common stock and will be dissolved, while RedCo II Offshore SPV became a more‑than‑5% holder. Redmile Group and Jeremy C. Green may be deemed to beneficially own 18,229,078 shares of common stock, or 14.9% of the class, including shares issuable from options, Class A Preferred Stock and Pre-Funded Warrants, with overall aggregate ownership unchanged.
Fate Therapeutics Inc ownership update: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Common Stock, representing 0% of the class as reported. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately. The amendment is signed on 03/26/2026.
Fate Therapeutics presents an in-depth annual overview of its strategy to develop off-the-shelf, iPSC-derived cellular immunotherapies for autoimmune diseases and cancer. The company engineers clonal iPSC master lines to mass-produce uniform T-cell and NK-cell therapies designed for on-demand, broad patient access.
The pipeline centers on FT819, a CD19-targeted CAR T-cell for systemic lupus erythematosus and other B cell–mediated autoimmune diseases, which has received FDA RMAT designation and shown early signals of deep B‑cell depletion and clinical activity with a fludarabine‑free or conditioning‑free approach. Additional programs include FT825 for HER2-positive solid tumors, FT836 and FT839 next‑generation CAR T cells incorporating Sword & Shield and dual‑CAR designs, and FT522, a CAR NK cell using Alloimmune Defense Receptor technology to reduce reliance on intensive chemotherapy.
The report highlights a broad risk profile typical for early-stage biotechnology, including heavy funding needs, clinical and regulatory uncertainty, complex manufacturing, reliance on partners such as Ono Pharmaceutical, and extensive dependence on patents and licensed technologies to protect its iPSC platform and product candidates.
Fate Therapeutics, Inc. reported fourth-quarter and full-year 2025 results and highlighted progress in its off-the-shelf CAR T-cell pipeline. For 2025, collaboration revenue was $6.6 million, down from $13.6 million in 2024, reflecting lower partnered activity. Total operating expenses fell sharply to $154.4 million from $223.9 million, driven by lower research and development and general and administrative costs, including reduced stock-based compensation and the absence of prior-year impairment.
The company’s 2025 net loss narrowed to $136.3 million from $186.3 million, with basic and diluted net loss per share improving to $1.15 from $1.64. As of December 31, 2025, Fate held $205.1 million in cash, cash equivalents, and investments, and common shares outstanding were 115.4 million. Management projects an operating runway through year-end 2027, supported by this cash position and an expected 30% reduction in 2025 operating expenses versus 2024, which they believe will enable key clinical and collaboration milestones.
Operationally, the company advanced FT819, its off-the-shelf CD19 CAR T-cell program for autoimmune diseases, including outpatient treatment and enrollment across 16 sites, and reported early clinical activity for FT836 in colorectal cancer without conditioning chemotherapy, alongside preclinical progress for FT839.
Fate Therapeutics reported new equity awards to Chief Legal and Compliance Officer Cindy Tahl. On January 15, 2026, she was granted 100,000 shares of common stock at an acquisition price of $0.00, reported as an award of restricted stock units. These RSUs vest in four equal installments on January 8, 2027, 2028, 2029 and 2030, with each RSU converting into one share of common stock upon settlement. Following this grant, she beneficially owns 487,081 common shares directly.
She was also granted a stock option for 400,000 shares of common stock with an exercise price of $1.05 per share. This option vests in 36 equal monthly installments after January 1, 2026, becoming fully vested and exercisable on January 1, 2029, contingent on continued service with the company.
Fate Therapeutics Chief Financial Officer Adawi Kamal reported new equity awards, including restricted stock units and stock options. On January 15, 2026, Kamal received 25,000 restricted stock units that vest in four equal installments on January 8 of each year from 2027 through 2030, subject to continued service. Each unit represents the right to receive one share of common stock upon settlement.
Kamal was also granted stock options for 75,000 shares of common stock at an exercise price of $1.05 per share. These options vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, if service continues. After these grants, Kamal beneficially owned 100,000 shares of common stock directly and held 75,000 stock options.
Fate Therapeutics reported that its President and CEO, Bahram Valamehr, received new equity awards. On January 15, 2026, he was granted 335,000 shares of common stock at a price of $0.00, representing restricted stock units that vest in four equal parts on January 8 of 2027, 2028, 2029 and 2030, contingent on continued service. On the same date, he was also granted a stock option for 1,300,000 shares of common stock at an exercise price of $1.05 per share, vesting in 36 equal monthly installments after January 1, 2026, and becoming fully vested on January 1, 2029, subject to continued service. Following the stock award, he beneficially owned 664,708 shares of common stock directly, and held 1,300,000 stock options directly.
Fate Therapeutics Chief Legal and Compliance Officer Cindy Tahl reported an automatic sale of company stock tied to restricted stock unit (RSU) vesting. On January 9, 2026, she sold 10,589 shares of common stock at a weighted average price of $1.0648 per share, with individual sale prices ranging from $1.05 to $1.09. The filing explains these were the required number of shares sold to cover tax withholding obligations arising from the vesting of 17,500 RSU-based shares granted on January 15, 2025 and 8,326 RSU-based shares granted on January 25, 2022. The transactions were executed under a pre-arranged “sell-to-cover” election and were not made at her discretion. After the sales, Tahl beneficially owned 387,081 shares of Fate Therapeutics common stock directly.